Orthofix Names New BOD Chair

Spine and orthopedics company Orthofix Medical Inc. has appointed Orthofix veteran Michael Finegan chair of the Orthofix Board of Directors.

Finegan replaces Catherine Burzik who was re-appointed chair of the Orthofix BOD in June 2023. Burzik had previously served as the chair of the Orthofix BOD from 2021 to 2022.

Orthofix President and CEO Massimo Calafiore expressed gratitude and excitement. Calafiore stated, “We are grateful to former Chair Cathy Burzik for her outstanding leadership, and I would like to thank her for all she has done for Orthofix and wish her the best as she continues to make a difference in the healthcare industry.”

Calafiore continued, “We are also excited to welcome Michael as our new Chair. His years of experience in the industry and specifically with Orthofix, will provide the Board with an important dimension and a tremendously valuable perspective to take us into our next chapter of growth.”

Finegan is currently the CEO at Acera Surgical, a bioscience company. However, he is no stranger to Orthofix. He has been serving on the Orthofix BOD since December 2023. He also spent 14 years with Orthofix before joining Acera.

Prior to joining Acera, Finegan served in roles of increasing responsibility with Orthofix. Most notably, he served as chief strategy officer for seven years. He also held other positions at Orthofix including President U.S. extremity and SVP business development, president biologics and SVP business development, and vice president corporate development.

Finegan commented, “I have a long history with Orthofix, and it is an honor to be selected to lead the Board of Directors.”

Finegan continued, “The company has undergone a transformation and I believe is well-positioned to deliver profitable growth and significant, sustainable shareholder value as we fulfill our mission of providing life-changing solutions for patients.”